Liminatus Pharma (LIMN) Stock Forecast and Price Target (2026)
Last updated November 2026
Short answer
There is no meaningful price-target consensus for Liminatus Pharma (LIMN): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. No analyst publishes estimates on it either. What is left is the latest reported figures, the drivers and the risks below, which you assess yourself. Walnut is not an investment adviser.
Why LIMN has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. LIMN is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.
For a clinical-stage biotech with no revenue, traditional metrics like P/E or price-to-sales do not apply, so the numbers that matter are cash on hand, the cash burn, and the runway between them. Here the runway is very short: a trailing net loss of about $12.5 million and operating cash outflow near $4 million against roughly $3 million in cash means the company must keep raising money to operate, which is why management disclosed going concern doubt. Read the roughly $4 million market cap as the market's small, heavily discounted estimate of a binary pipeline rather than a multiple of any earnings, and treat each financing and clinical update as the real value driver.
LIMN: the latest reported figures
No analyst publishes estimates on LIMN, so these are the most recent figures we hold, as of October 2026 (financials through the quarter ended June 30, 2026). They describe where the company stands, not where it is going.
- Revenue: $0 (no approved products)
- Net loss (TTM): ~$12.5 million
- Net loss (FY2025): ~$10.2 million
- Cash / debt: ~$3.0 million / ~$1.4 million (Jun 30, 2026)
- Shares outstanding: ~1.34 million after the 1-for-50 reverse split
- Market cap: ~$4 million (share price ~$3.11)
Is there a 2030 forecast for LIMN?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering LIMN do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Liminatus Pharma can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move LIMN from here
In short: the drivers cited most often are Lead anti-CD47 program, Pipeline breadth and the InnocsAI deal, Financing is the immediate driver. The risk cited most often against it is liminatus carries the full stack of risks that define a distressed pre-revenue biotech.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the LIMN is it a buy page.
Your questions about Liminatus Pharma
Ask Walnut's AI anything about LIMN and see how it fits what you own.
FAQ
What is the price target for Liminatus Pharma (LIMN)?
+
There is no meaningful consensus price target for LIMN, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does LIMN have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean the analysis starts with you, because there is no published model to build on.
What could move LIMN?
+
The drivers and the risks are laid out on this page and in more depth on the LIMN "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.